Notice

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs 2024.01.01

Notice

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI

JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimert 2024.01.01

Notice

Yuhan Corporation Partners with J INTS BIO for 'HER2 Target TKI'

Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN 2024.01.01

Notice

J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC

SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' target 2023.12.09

Notice

J INTS BIO, Oral TKI 'JIN-A04', poster presentation of HER2 exon20 insertion mutation in NSCLC

SEOUL, South Korea, Feb. 6, 2023 /PRNewswire/ -- J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibito 2023.02.07

Notice

J INTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor 'JIN-001', presentation of preclinical assessment at 2022 SNO Annual Meeting

SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally adminis 2022.11.23

Notice

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA

- First patient expected in December 2022SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received a 2022.11.10

Notice

J INTS BIO’s Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ effective against both cis and trans isomers of C797S mutations - ESMO 2022

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR- 2022.09.16

Notice

J INTS BIO successfully held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR TKI (JIN-A02) in Vienna, Austria during WCLC

SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4t 2022.08.19